Cytokinetics develops heart-muscle drugs, led by aficamten.
Cytokinetics, Incorporated (CYTK) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:05 ET. Consensus EPS estimate is $-1.45.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $-1.63 | $-1.50 | +8.0% | $31.91M |
| 2026-05-05 | Mar 2026 qtr | $-1.67 | $-1.67 | +0.0% | $19.36M |
| 2026-02-26 | Dec 2025 qtr | $-1.48 | $-1.49 | -0.7% | $17.75M |
| 2025-11-05 | Sep 2025 qtr | $-1.59 | $-2.55 | — | $1.94M |
| 2025-08-07 | Jun 2025 qtr | $-1.34 | $-1.12 | — | — |
| 2025-05-06 | Mar 2025 qtr | $-1.41 | $-1.36 | +3.5% | $1.58M |
| 2025-02-27 | Dec 2024 qtr | $-1.29 | $-1.27 | +1.6% | $16.93M |
| 2024-05-10 | Mar 2024 qtr | $-1.16 | $-1.33 | -14.7% | $835.00K |
CYTK has beaten consensus EPS in 4 of its last 6 scored quarters.
See CYTK on the live calendar →